Combination of HGF/IL-22 mRNAs delivered by GalNAc-lipid nanoparticles to treat acute liver injury

Puntos clave

• HGF and IL-22 mRNAs delivered via nanoparticles improved recovery in liver injury models, indicating promising therapeutic potential.
• Key metrics include significant reduction in liver injury markers and enhanced repair processes following treatment.
• Assessment used a novel delivery system involving GalNAc-lipid nanoparticles to efficiently target liver cells for mRNA delivery.
• Results support the need for further exploration into mRNA-based therapies for liver injury, highlighting potential in clinical applications.